Share of Clicks for top 10 US Pharma & Biotech Infectious Diseases brands
Here are the Top 10 competitors in the industry by Share of Clicks for the last month.
| Domain | Share of clicks |
|---|---|
| paxlovid.com | 20.09 |
| uqora.com | 8.8 |
| cabenuva.com | 7.69 |
| mavyret.com | 7.37 |
| admired.com | 5.87 |
| prevnar20.com | 5.72 |
| symtuzahcp.com | 4.96 |
| goodrx.com | 4.43 |
| dovato.com | 3.77 |
| epclusa.com | 3.31 |
| others | 27.99 |
- paxlovid.com - 20.09%
- uqora.com - 8.8%
- cabenuva.com - 7.69%
- mavyret.com - 7.37%
- admired.com - 5.87%
- prevnar20.com - 5.72%
- symtuzahcp.com - 4.96%
- goodrx.com - 4.43%
- dovato.com - 3.77%
- epclusa.com - 3.31%
- others - 27.99%
Copyright © Adthena. All rights reserved.
In the PPC landscape, paxlovid.com leads with 20.09% click share, followed by uqora.com at 8.8%. ‘Others’ collectively hold a significant 27.99%, showcasing diverse competition.
Share of Spend for the top 10 US Pharma & Biotech Infectious Diseases brands
Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month.
| Date | cabenuva.com | admired.com | dovato.com | uqora.com | paxlovid.com | symtuzahcp.com | cabenuvahcp.com | mavyret.com | prevnar20.com | epclusa.com |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/08/01 | 9.33% | 11.42% | 5.7% | 16.73% | 3.76% | 3.38% | 2.02% | 6.11% | 3.93% | 2.76% |
| 2026/08/02 | 15.65% | 1.43% | 7.6% | 11.19% | 4.99% | 2.43% | 4.98% | 9.66% | 4.17% | 3.65% |
| 2026/08/03 | 12.45% | 6.81% | 9.78% | 7.87% | 6.1% | 1.45% | 3.43% | 8.83% | 5.84% | 2.88% |
| 2026/08/04 | 18.32% | 1.26% | 7.93% | 4.66% | 3.76% | 0.55% | 3.81% | 7.32% | 5.37% | 5.51% |
| 2026/08/05 | 25.91% | 0% | 10.56% | 0% | 6.92% | 1.09% | 7.15% | 2.37% | 8.32% | 4.82% |
| 2026/08/06 | 21.71% | 0% | 11.89% | 8.62% | 6.94% | 1.13% | 6.53% | 6.01% | 6.88% | 4.83% |
| 2026/08/07 | 22.07% | 0% | 10.97% | 1.92% | 6.74% | 6.95% | 6.64% | 1.42% | 8.06% | 4.37% |
| 2026/08/08 | 25.2% | 0% | 12.9% | 2.53% | 10.45% | 0.81% | 8.89% | 1.24% | 11.57% | 3.73% |
| 2026/08/09 | 15.71% | 12.61% | 6.25% | 11.88% | 4.35% | 2.77% | 3.54% | 1.21% | 4.96% | 2.4% |
| 2026/08/10 | 19.37% | 7.31% | 5.89% | 6.99% | 5.19% | 7.75% | 6.69% | 2.48% | 5.47% | 3.28% |
| 2026/08/11 | 12.76% | 11.25% | 8.71% | 8.64% | 4.25% | 5.11% | 3.37% | 3.3% | 6.66% | 2.84% |
| 2026/08/12 | 15.03% | 0% | 13.47% | 0% | 4.85% | 10.66% | 5.23% | 7.89% | 7.55% | 4.21% |
| 2026/08/13 | 11.42% | 0% | 12.46% | 1.45% | 5.42% | 6.59% | 4.94% | 8.51% | 8.55% | 9.99% |
| 2026/08/14 | 10.16% | 0% | 11.35% | 0% | 5.4% | 12.84% | 4.32% | 8.14% | 7.83% | 9.31% |
| 2026/08/15 | 15.49% | 0% | 11.18% | 1.39% | 5.37% | 5.7% | 4.77% | 10.23% | 7.8% | 8.62% |
| 2026/08/16 | 11.67% | 1.07% | 8.43% | 4.8% | 3.85% | 11.58% | 3.59% | 6.2% | 4.87% | 3.25% |
| 2026/08/17 | 10.08% | 7.56% | 8.4% | 6.99% | 3.38% | 8.43% | 3.16% | 9.29% | 4.69% | 5.02% |
| 2026/08/18 | 18.61% | 9.05% | 7.18% | 8.38% | 4.97% | 6.14% | 4.36% | 2.84% | 4.76% | 4.59% |
| 2026/08/19 | 22.43% | 0% | 12.55% | 0% | 7.49% | 7.48% | 6.64% | 4.06% | 8.34% | 4.52% |
| 2026/08/20 | 16.67% | 4.32% | 5.83% | 4% | 4.38% | 11.35% | 4.83% | 9.78% | 4.03% | 1.91% |
| 2026/08/21 | 18.38% | 6.92% | 8.19% | 6.4% | 5.39% | 4.77% | 5.46% | 2.14% | 5.38% | 3.04% |
| 2026/08/22 | 20.76% | 1.93% | 9.01% | 7.13% | 5.78% | 4.28% | 6.06% | 8.82% | 4.48% | 3.66% |
| 2026/08/23 | 26.02% | 0% | 8.28% | 3.97% | 6.52% | 5.79% | 6.17% | 4.32% | 8.36% | 5.71% |
| 2026/08/24 | 19.32% | 8.06% | 12.43% | 7.46% | 6.42% | 1.85% | 5.83% | 2.45% | 6.74% | 3.26% |
| 2026/08/25 | 23.34% | 0% | 10.42% | 4.18% | 7.39% | 4.63% | 7.07% | 3.09% | 8.9% | 4.19% |
| 2026/08/26 | 24.62% | 0% | 12.06% | 2.07% | 6.59% | 5.5% | 7.02% | 2.19% | 8.72% | 2.62% |
| 2026/08/27 | 21.97% | 0% | 11.26% | 4.19% | 7.03% | 8.88% | 6% | 4.67% | 7.57% | 5.75% |
| 2026/08/28 | 23.1% | 0% | 9.23% | 1.73% | 5.09% | 2.62% | 5.86% | 4.01% | 7.63% | 1.76% |
| 2026/08/29 | 18.93% | 0% | 11.52% | 4.32% | 7.21% | 3.97% | 7.32% | 5.87% | 8.55% | 2.68% |
| 2026/08/30 | 16.17% | 4.83% | 9.88% | 4.47% | 4.55% | 2.27% | 4.61% | 3.15% | 4.52% | 3.66% |
| 2026/08/31 | 13.74% | 10.65% | 8.52% | 7.5% | 5.89% | 4.5% | 4.31% | 4.07% | 3.86% | 2.81% |
- cabenuva.com
- admired.com
- dovato.com
- uqora.com
- paxlovid.com
- symtuzahcp.com
- cabenuvahcp.com
- mavyret.com
- prevnar20.com
- epclusa.com
Copyright © Adthena. All rights reserved.
Cabenuva.com led August with fluctuating spend, peaking mid-month. Admired.com showed sporadic activity, while Dovato.com maintained steady growth. Uqora.com and Paxlovid.com had varied trends. Symtuzahcp.com and Cabenuvahcp.com saw moderate increases. Mavyret.com, Prevnar20.com, and Epclusa.com displayed consistent patterns.
Competitor Count for US Pharma & Biotech Infectious Diseases
Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month.
| Date | Competitor Count |
|---|---|
| 2026/08/01 | 79 |
| 2026/08/02 | 80 |
| 2026/08/03 | 76 |
| 2026/08/04 | 75 |
| 2026/08/05 | 66 |
| 2026/08/06 | 68 |
| 2026/08/07 | 65 |
| 2026/08/08 | 61 |
| 2026/08/09 | 65 |
| 2026/08/10 | 63 |
| 2026/08/11 | 62 |
| 2026/08/12 | 65 |
| 2026/08/13 | 62 |
| 2026/08/14 | 62 |
| 2026/08/15 | 64 |
| 2026/08/16 | 72 |
| 2026/08/17 | 68 |
| 2026/08/18 | 69 |
| 2026/08/19 | 66 |
| 2026/08/20 | 70 |
| 2026/08/21 | 67 |
| 2026/08/22 | 67 |
| 2026/08/23 | 64 |
| 2026/08/24 | 63 |
| 2026/08/25 | 60 |
| 2026/08/26 | 60 |
| 2026/08/27 | 59 |
| 2026/08/28 | 62 |
| 2026/08/29 | 63 |
| 2026/08/30 | 67 |
| 2026/08/31 | 66 |
Copyright © Adthena. All rights reserved.
August began with 79 advertisers, peaking at 80, then fluctuating. By month’s end, it settled at 66.
